Athersys Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,438.00
1,623.00
11,948.00
17,347.00
3,708.00
24,291
Cost of Goods Sold (COGS) incl. D&A
-
360.00
-
-
-
-
Gross Income
-
1,263.00
-
-
-
-
SG&A Expense
26,549.00
30,275.00
28,852.00
32,673.00
31,607.00
45,398
EBIT
24,457.00
29,012.00
17,171.00
15,708.00
28,583.00
21,962
Unusual Expense
6,324.00
6,591.00
772.00
125.00
3,972.00
3,083
Non Operating Income/Expense
38.00
86.00
61.00
209.00
314.00
762
Pretax Income
30,743.00
22,335.00
16,460.00
15,374.00
32,241.00
24,283
Income Tax
-
253.00
38.00
37.00
-
-
Consolidated Net Income
30,743.00
22,082.00
16,422.00
15,337.00
32,241.00
24,283
Net Income
30,743.00
22,082.00
16,422.00
15,337.00
32,241.00
24,283
Net Income After Extraordinaries
30,743.00
22,082.00
16,422.00
15,337.00
32,241.00
24,283
Net Income Available to Common
30,743.00
22,082.00
16,422.00
15,337.00
32,241.00
24,283
EPS (Basic)
0.53
0.31
0.20
0.18
0.29
0.18
Basic Shares Outstanding
57,674.80
76,955.00
82,143.60
84,715.50
112,053.40
136,641
EPS (Diluted)
0.53
0.31
0.20
0.18
0.29
0.18
Diluted Shares Outstanding
57,674.80
78,541.00
82,851.10
84,715.50
112,053.40
136,641
EBITDA
24,111.00
28,652.00
16,904.00
15,326.00
27,899.00
21,107

About Athersys

View Profile
Address
3201 Carnegie Avenue
Cleveland Ohio 44115
United States
Employees -
Website http://www.athersys.com
Updated 07/08/2019
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J.